68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

• Status: Recruiting
• Trial end date: 2024-07-21
• Target enrollment: 0
• Participant gender: All

Summary

This early phase I trial studies an imaging technique called 68Ga-FAPi-46 PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with sarcoma. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi. Because some cancers take up 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jonsson Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: FAPI-46

Criteria

Inclusion Criteria:

• Patients who underwent a 18F-FDG PET/CT scan within 3 months of enrollment.

• Patients who are scheduled to undergo surgical excision or biopsy of a sarcoma primary, recurrent or metastatic lesion.

• Patients who can provide written informed consent.

• Patients who are able to remain still for duration of imaging procedure (up to one hour).

Exclusion Criteria:

• Patients with any new sarcoma therapy between the 18F-FDG PET/CT and the FAPI PET/CT.